Information letter to health care professionals regarding the safe use of the medicinal product MERIGEN (drospirenone/ethinylestradiol). Risk of venous and arterial thromboembolism with the use of combined hormonal contraceptives
19.01.2026
463
Direct Healthcare Professional Communication letter for healthcare professionals on the risk of venous and arterial thromboembolism associated with the use of combined hormonal contraceptives, in particular the product MERIZHEN. Contains data from the EU-wide review, recommendations on taking individual risk factors into account, and signs of thromboembolism. generated automatically
Read more
